Adrián LLerena
Instituto de Salud Carlos III(ES)Government of Extremadura(ES)Red de Investigación en Sida(ES)Centro de Investigación Biomédica en Red de Salud Mental(ES)Centre for Biomedical Network Research on Rare Diseases(ES)Fondazione Farmacogenomica FiorGen(IT)Centro Tecnológico Agroalimentario de Extremadura(ES)Centro de Implantología Cirugía Oral y Maxilofacial(ES)Universidad de Extremadura(ES)
Publications by Year
Research Areas
Pharmacogenetics and Drug Metabolism, Schizophrenia research and treatment, Drug Transport and Resistance Mechanisms, Pharmacological Effects and Toxicity Studies, Treatment of Major Depression
Most-Cited Works
- → Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors(2015)958 cited
- → Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test.(1994)307 cited
- → An International Adult Guideline for Making Clozapine Titration Safer by Using Six Ancestry-Based Personalized Dosing Titrations, CRP, and Clozapine Levels(2021)241 cited
- → Pharmacokinetics of losartan and its metabolite E‐3174 in relation to the CYP2C9 genotype(2002)182 cited
- → Interethnic variation of CYP2C19 alleles, ‘predicted’ phenotypes and ‘measured’ metabolic phenotypes across world populations(2015)165 cited
- → Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and HLA‐B Genotypes and Phenytoin Dosing: 2020 Update